Caribou_logo.png
Caribou Biosciences Expands Clinical Development of CB-010 with FDA Clearance of IND in Lupus
April 04, 2024 16:00 ET | Caribou Biosciences, Inc.
-- FDA has cleared Caribou’s IND application for CB-010 in lupus nephritis and extrarenal lupus; GALLOP Phase 1 clinical trial expected to initiate by YE 2024 -- -- Driven by encouraging initial...
Caribou_logo.png
Caribou Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
March 11, 2024 16:05 ET | Caribou Biosciences, Inc.
-- 30th patient dosed in CB-010 ANTLER Phase 1 trial dose expansion; initial dose expansion data and RP2D to be disclosed in Q2 2024 -- -- 1st patient dosed in CB-012 AMpLify Phase 1 trial for...
Caribou_logo.png
Caribou Biosciences to Present Preclinical Data on CB-012, an Allogeneic Anti-CLL-1 CAR-T Cell Therapy, at the American Association for Cancer Research (AACR) Annual Meeting
March 05, 2024 16:30 ET | Caribou Biosciences, Inc.
BERKELEY, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced that...
Caribou_logo.png
Caribou Biosciences to Participate in Upcoming Investor Conferences
February 15, 2024 16:05 ET | Caribou Biosciences, Inc.
BERKELEY, Calif., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the company’s...
market-digits.jpg
Gene Switch/Molecular Switch Market projected to reach USD 1.4 Billion by 2030, growing at a CAGR of 11.3% during the forecast period of 2023-2030 - pronounced by MarketDigits in its recent study Richmond, Feb. 15, 2024 (GLOBE NEWSWIRE) -- According to a research report "Gene Switch/Molecular Switch Market”, by Product Type (CAR-T Cell Therapies, Gene Therapies, Others), Payment model...
Tim Kelly_CTO
Caribou Biosciences Appoints Tim Kelly as Chief Technology Officer and Highlights Multiple Clinical Catalysts Expected in 2024
January 07, 2024 11:00 ET | Caribou Biosciences, Inc.
-- Tim Kelly to lead Caribou’s technical operations strategy and execution -- -- CB-010 ANTLER Phase 1 trial initial dose expansion data and RP2D to be disclosed Q2 2024; Caribou plans to initiate...
Caribou_logo.png
Caribou Biosciences Provides Regulatory Update on CB-010 Pivotal Plan with Phase 3 Trial Initiation Expected by YE 2024
December 12, 2023 16:02 ET | Caribou Biosciences, Inc.
-- Caribou met with the FDA and reached alignment on a pivotal trial in 2L LBCL with CB-010 versus a comparator arm of immunochemotherapy followed by HDCT and ASCT -- -- ANTLER Phase 1 trial...
Caribou_logo.png
Caribou Biosciences Reports Third Quarter 2023 Financial Results and Provides Business Update
November 07, 2023 16:00 ET | Caribou Biosciences, Inc.
-- CB-010 ANTLER Phase 1 trial continues enrolling second-line r/r LBCL patients in dose expansion; plan to share FDA feedback by year-end 2023 and report initial dose expansion data in H1 2024 -- ...
Caribou_logo.png
Caribou Biosciences Announces Appointment of Sundar Jagannath, MD, to its Scientific Advisory Board
November 06, 2023 08:00 ET | Caribou Biosciences, Inc.
-- Dr. Jagannath is a renowned expert in the research and treatment of multiple myeloma -- BERKELEY, Calif., Nov. 06, 2023 (GLOBE NEWSWIRE) --  Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading...
Caribou_logo.png
Caribou Biosciences to Participate in Upcoming Investor Conferences
November 01, 2023 16:05 ET | Caribou Biosciences, Inc.
BERKELEY, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the company’s...